Marvel Biosciences Corp. (MRVL.V)
- Baystreet
Stocks in play: Marvel Biosciences Corp
Announces that it has successfully completed a multi-kilogram scale run under current good manufacturing ...
- Newsfile
Marvel Biosciences Completes a Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer's Disease and Depression
Calgary, Alberta--(Newsfile Corp. - January 6, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company " or "Marvel "), are pleased to announce that it has successfully completed a multi-kilogram scale run under current good manufacturing practices ("cGMP") of the active pharmaceutical ingredient (API) of the Company's lead asset MB-204 in partnership with Zhejiang Ausun Pharmaceutical Co., Ltd. ("Ausun"). The cGMP mater
- Newsfile
Marvel Biosciences Successfully Completes its Short Term Dose Ranging Study in Rats and Dogs for MB-204
Calgary, Alberta--(Newsfile Corp. - January 3, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has successfully completed its dose-ranging toxicology studies in rats and dogs, for its lead drug candidate MB-204. These studies will assist in determining the doses for the IND-enabling 4-week GLP toxicology studies."We are looking forward to initiating the 4-week toxicol
